Cervical cancer
Conditions
Interventions
Control group: Radiotherapy (RT)+ Chemotherapy (CHT)
RT: 50Gy of external RT in 25 sessions of 2Gy each, followed by 85-90Gy of brachytherapy.
CHT: Cisplatin by intravenous route, weekly during RT at
Radiotherapy
Brachytherapy
Cisplatin
Chemoradiotherapy
Drug Therapy
Administration, Intravenous
Paclitaxel
Sponsors
Cancerology State Institute, Colima State Health Service (SSA-Colima), Mexico
Medical School of the University of Colima, Mexico
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Women older than 18 years 2. Clinical and histological diagnosis of CaCU EC IIB-IVA. 3. Histology of epidermoid carcinoma, adenocarcinoma, adenosquamous. 4. ECOG 0-2. 5. Patients with no history of Hepatic insufficiency or creatinine clearance less than 30mil / min. 6. Patients without sensory or motor neuropathy from any cause
Exclusion criteria
Exclusion criteria: 1. Histology of small cells. 2. ECOG 3 or greater. 3. Diagnosis of second primary cancer. 4. Patients with diagnosed pregnancy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete response (RECIST 1.1). Measuring time: 12 weeks. | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse Events (According to Common Terminology of Criteria for Adverse Events (CTCAE) version 3). Measurement time: Every week until week 12. | — |
Countries
Mexico
Contacts
Public ContactIvan Delgado-Enciso
Cancerology State Institute, Colima State Health Service
Outcome results
None listed